HSP90AA1 and neoplasm: While the cause of the heterogeneous responses from different tumor cell lines to Hsp90 inhibitors remains little beyond speculations, such as post-translational modifications and multiple oncogenic factors in the cells, the above observations could have posted serious challenges for the patient selection processes of the previous clinical trials.